ABIVAX Société Anonyme (NASDAQ:ABVX) Receives Average Recommendation of “Buy” from Analysts

Shares of ABIVAX Société Anonyme (NASDAQ:ABVX) have received an average recommendation of “Buy” from the seven ratings firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $38.67.

Several brokerages have commented on ABVX. JMP Securities reaffirmed a “market outperform” rating and issued a $33.00 target price on shares of ABIVAX Société Anonyme in a research note on Friday, January 10th. Citizens Jmp upgraded shares of ABIVAX Société Anonyme to a “strong-buy” rating in a research report on Wednesday, December 4th.

Hedge Funds Weigh In On ABIVAX Société Anonyme

Large investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC acquired a new position in shares of ABIVAX Société Anonyme during the fourth quarter worth about $29,000. Point72 Asset Management L.P. grew its stake in shares of ABIVAX Société Anonyme by 28.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock worth $6,254,000 after acquiring an additional 119,300 shares in the last quarter. Walleye Capital LLC raised its holdings in shares of ABIVAX Société Anonyme by 45.8% in the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock valued at $2,965,000 after purchasing an additional 80,807 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in shares of ABIVAX Société Anonyme by 82.6% in the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock valued at $150,000 after purchasing an additional 5,900 shares during the last quarter. Finally, abrdn plc lifted its position in shares of ABIVAX Société Anonyme by 167.7% in the third quarter. abrdn plc now owns 316,431 shares of the company’s stock worth $3,645,000 after purchasing an additional 198,225 shares in the last quarter. Institutional investors own 47.91% of the company’s stock.

ABIVAX Société Anonyme Stock Performance

ABIVAX Société Anonyme stock opened at $6.23 on Thursday. The business has a 50-day moving average of $7.72 and a 200-day moving average of $10.05. ABIVAX Société Anonyme has a 1 year low of $5.54 and a 1 year high of $17.02.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.